BACK (IMAC Holdings) 3-Year RORE % : -28.39% (As of Sep. 2025)


What is IMAC Holdings 3-Year RORE %?

IMAC Holdings BACK 3-Year RORE % is -28.39 as of Sep. 2025. The stock has 7 warning signs investors should review. Among 607 Healthcare Providers & Services companies, IMAC Holdings ranks worse than 73.48% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. IMAC Holdings's 3-Year RORE % for the quarter that ended in Sep. 2025 was -28.39%.

The industry rank for IMAC Holdings's 3-Year RORE % or its related term are showing as below:

BACK's 3-Year RORE % is ranked worse than
73.48% of 607 companies
in the Healthcare Providers & Services industry
Industry Median: 0.74 vs BACK: -28.39

IMAC Holdings  (OTCPK:BACK) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


IMAC Holdings 3-Year RORE % Related Terms


IMAC Holdings 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for IMAC Holdings's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IMAC Holdings 3-Year RORE % Chart

IMAC Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only 4.96 -16.32 8.06 -17.57 -33.92

IMAC Holdings Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.11 -33.92 -33.57 -34.89 -28.39

BACK vs FCHS, NHLG, NIVF: 3-Year RORE % Comparison

For the Medical Care Facilities subindustry, IMAC Holdings's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IMAC Holdings 3-Year RORE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, IMAC Holdings's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where IMAC Holdings's 3-Year RORE % falls into.



IMAC Holdings 3-Year RORE % Calculation

IMAC Holdings's 3-Year RORE % for the quarter that ended in Sep. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -6.72--14.04 )/( -25.78-0 )
=7.32/-25.78
=-28.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -28.39 mean?
IMAC Holdings (BACK) has a 3-Year RORE % of -28.39 as of Sep. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on IMAC Holdings and its competitors. According to the industry distribution chart, IMAC Holdings ranks #446 out of 607 companies in the Healthcare Providers & Services industry, placing it in the top 73.5%.
Is IMAC Holdings' 3-Year RORE % too high?
IMAC Holdings' current 3-Year RORE % is -28.39. Based on the distribution chart, IMAC Holdings ranks #446 out of 607 companies in the Healthcare Providers & Services industry, which is below the industry midpoint.
How does IMAC Holdings' 3-Year RORE % compare to FCHS and NHLG?
According to the Healthcare Providers & Services industry distribution chart, IMAC Holdings ranks #446 out of 607 companies for 3-Year RORE %. This places IMAC Holdings in the lower half of its industry. The industry median 3-Year RORE % is 0.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 0.74, based on 607 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on IMAC Holdings and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 0.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IMAC Holdings's current 3-Year RORE % is -28.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IMAC Holdings stock overvalued right now?
IMAC Holdings (BACK) has a current 3-Year RORE % of -28.39. The current 3-Year RORE % is -28.39. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For IMAC Holdings (BACK), the current 3-Year RORE % is -28.39 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IMAC Holdings Business Description

Address 3401 Mallory Lane, Suite 100, Franklin, TN, USA, 37067
IMAC Holdings Inc is engaged in providing services related to proteomic products that identify and support oncology clinical treatment decisions and biopharmaceutical drug development. The Company has determined that it currently operates in a single segment, precision medicine in cancer treatment, located in a single geographic location, the United States.